PCa Commentary | Volume 139 – October 2019

OLIGOMETASTATIC PROSTATE CANCER: Is It an Intermediate Stage of Cancer, and If So, How Should It Be treated?

It has been suggested that a few (usually 3-5, i.e., ‘oligometastatic’) lesions at the time of biochemical failure after primary treatment might represent an indolent disease state with limited potential for additional spread. This hypothesis was first made in 1995 by Hellman and Weichselbaum (J Clin Oncol). Those authors’ thoughts were paraphrased by Tran and Antonarakis (J Oncol Pract. 2016) in “Altering the Natural History of Oligometastatic Prostate Cancer with Local Therapies: Reality Versus Illusion.”

PCa Commentary | Volume 138 – September 2019

Active Surveillance: Update and New Developments

This issue reviews the current state of active surveillance with an article from Laurence Klotz, MD, entitled “Active Surveillance for Prostate Cancer: How to Do It Right.” This Commentary covers the role of multiparametric MRI and genomic testing panels in carefully selecting and following prostate cancer patients who choose active surveillance in order to safely delay primary treatment and achieve excellent outcomes.

PCa Commentary | Volume 137 – August 2019

Radium-223 (‘Xofigo’): A Radioisotope Treatment for Bone Metastases – Where Does It Fit in the Management of Prostate Cancer?

This issue reviews the clinical significance of bone metastases in castrate-resistant prostate cancer (CRPC) patients, the mechanism of action of radium-223, and the isotope’s utility in managing these patients. This Commentary also features take-away points from a lecture titled “Real World Treatment Experience with Radium-223” by Daniel George, MD, on the role of radium-223 in the schema of metastatic CRPC treatment.

PCa Commentary | Volume 136 – July 2019

The Natural History of Prostate Cancer and the Prognostic Utility of PSA Doubling Time.

This issue reviews a report Catherine H. Marshall, MD, MPH, presented at the 2019 ASCO Annual Meeting, entitled “Outcomes of Men with Recurrent M0 Prostate Cancer Who Defer Androgen Deprivation Therapy Until Metastasis – Medical Oncologist Perspective.” The discussion will analyze outcome data from three retrospective related observation trials included in Dr. Marshall’s report, and how PSA doubling time can guide appropriate timing of hormone suppression initiation so as to balance the dual goals of delaying metastases and avoiding the toxicity of therapy.

PCa Commentary | Volume 135 – June 2019

Managing PSA Recurrence Following Primary Radiation Therapy: Evolving Regimens for Focal Treatment.

Biochemical recurrence following primary irradiation is relatively common. “A recent series of 2694 patients treated with doses above 78 Gy revealed 10-year biochemical recurrence risks of approximately 10%, 23%, and 44% in low-, intermediate-, and high-risk patients, respectively. […] After primary whole-gland radiotherapy several series showed that nearly all recurrences (89-100%) regrow at the site of the primary largest and/or highest-grade index lesion,” as quoted in “Focal Salvage Treatment of Radiorecurrent Prostate Cancer”, Marieke et al., Cancers (Basel). 2018 Dec. [An excellent review] This biology offers carefully selected patients the opportunity of treatment focused on the control of the local disease recurrence.

PCa Commentary | Volume 134 – May 2019

RADIOLIGAND THERAPY – The “VISION” Protocol: A treatment opportunity for men with late-stage metastatic castration-resistant prostate cancer.

Radioligand therapy (RLT), or in other words, PSMA directed endoradiation with Lutetium-177, has been developed to the extent that it is a realistic option for men with late-stage, heavily pretreated, metastatic castration-resistant prostate cancer. This therapy has been extensively studied in many trials with the general consensus that the treatment is safe with minimal adverse effects and consistently has led to a >50% decline in PSA in a range of ~40 to 60% of the men. This Commentary will highlight examples of these studies.

PCa Commentary | Volume 133 – April 2019

GENOMIC SEQUENCING FOR PROSTATE CANCER – Which Men Gain a Clinical Benefit from Genomic Testing?

The commonly cited goal of ‘personalized medicine’ in regards to treatment selection based on genomic testing is in the early ‘work in progress’ stage. Breathtaking advances in next generation sequencing (NGS) are very promising, but currently only limited options exist for therapeutic guidance. Dr. Oliver Sartor acknowledges this in the recent NEJM review, Metastatic Prostate Cancer, Feb 2018: “The use of advanced genomic analysis is now feasible to a greater extent than ever before. Whether its use improves treatment decisions is not yet clear.”

PCa Commentary | Volume 132 – March 2019

Resistance to Therapeutic Agents Targeting the Androgen Receptor and Insights into Sequencing Treatments for Optimal Outcomes

Ever since the first orchiectomy for metastatic prostate cancer in 1941, researchers and clinicians have been determinedly trying to restrain the androgen receptor (AR) by manipulating its hormone environment. But like Houdini, after initial suppression this wily adversary wriggles a bit and then escapes — transitioning prostate cancer into a castration-resistant state. Alterations in the AR eventually frustrate the beneficial gains from  LHRH inhibitors and anti-androgens like Zytiga, Xtandi, Erleada, etc. This escape is accomplished by a variety of different mechanisms, presenting the challenge of anticipating and circumventing the persistence of AR signaling.

PCa Commentary | Volume 131 – February 2019

ENZALUTAMIDE (‘XTANDI’): AN UPDATE: The Many Faces of Enzalutamide

Many important developments have taken place since Enzalutamide (ENZ) was reviewed in the March/April 2014 issue. This Commentary will discuss these developments and the current indications for ENZ and new studies of ENZ as monotherapy. A subsequent Commentary will address sequencing, resistance, and possible potentiation of immunotherapy.

PCa Commentary | Volume 130 – January 2019

Ga68-PSMA-11 PET/CT Scanning at Initial Diagnosis for High-Risk Prostate Cancer: What is missed by conventional staging and does it matter?

For this Commentary, eleven research papers reporting the results for the Ga68-PSMA PET/CT applied to high-risk prostate cancer were reviewed. For interest, here is the list of research locations: Australia (3, where the scan is readily available), India, Turkey, Germany (2), Jordan, and the USA (3, UCSF, UCLA, and Johns Hopkins).

PCa Commentary | Volume 129 – December 2018

THE AXUMIN PET/CT SCAN:  ITS CLINICAL UTILITY — AN UPDATE

It has been one year since the Commentary featured the Axumin PET/CT in the November 2017 issue.  A great deal of new research about this scan performance has been published since then. The material in this issue is based on this research. Overall, these studies focus on the Axumin scan, which provides clinically relevant information at PSA levels that lead to significant changes in treatment plans for a majority of men. 

PCa Commentary | Volume 128 – November 2018

IMMUNOTHERAPY FOR PROSTATE CANCER:
Immune Checkpoint Inhibitors — The Search for Clues for Which Men Will Benefit and How Best to Treat Them.

Harnessing our immune system to treat cancer has been an elusive goal for decades. Research in immunotherapy is intense with active study of the newest advances, i.e. checkpoint inhibitors and CAR T-cell technology. Checkpoint inhibitors have yielded encouraging results in selected patients (10% – 40% responding) with melanoma, bladder and kidney, non-small cell lung cancer, and cancer of the head and neck. However, the results of prostate cancer immunotherapy have been disappointing in unselected patients. Why is this?

PCa Commentary | Volume 127 –October 2018

DECIPHER AND A HYBRID CLINICAL – GENOMIC CLASSIFIER:
Improving the Prognostic Accuracy of NCCN Risk Categories

The article will discuss how Decipher is constructed, its benefits as a supplement to the standard risk assessments tools, and offer examples of its use in clinical practice. Additionally, the Commentary will highlight the work of Dr. Dan Spratt and colleagues that integrates the NCCN system with Decipher to achieve further prognostic accuracy (“Spratt, et al., Journal of Clinical Oncology, Feb. 2018”).

PCa Commentary | Volume 126 – September 2018

ESTROGEN — OUR SISTER HORMONE:
Addressing the Dark Side of Androgen Deprivation Therapy (ADT)

Many of the important adverse effects associated with androgen suppression with Lupron, Firmagon, or orchiectomy result from estrogen deficiency. Estimates vary, but 50%, 75%, or as much as 80% of a man’s serum estrogen arises from enzymatic conversion of serum testosterone. And when ADT drops serum testosterone into the low range of 20 – 30 ng/dL, a profound estrogen deficiency results.

PCa Commentary | Volume 125 – August 2018

NEUROENDOCRINE PROSTATE CANCER: An Adverse Development in Advanced Disease — Which Largely Has Flown Under the Radar.

Neuroendocrine prostate cancer (NEPC) is a form of the disease which, as best currently understood, arises from standard adenocarcinoma in a process termed “transdifferentiation.” This transformation develops in advanced stages of prostate cancer—usually in metastatic CRPC, and is thought to result as an adaptation to the selective pressure of androgen deprivation. It’s usually seen after prior therapy with, for example, abiraterone and/or enzalutamide and is one source of resistance to these agents.

PCa Commentary | Volume 124 – July 2018

ACTIVE SURVEILLANCE: EFFORTS TO IMPROVE ITS PERFORMANCE

The goal of active surveillance (AS) is to delay treatment, avoiding its associated adverse effects for as long as appropriate, while ensuring that selective delayed intervention will still result in a good outcome. This management strategy has been under development for more than 20 years. It has been increasingly accepted as an appropriate option for men with low-risk disease, but further refinement is required in patient selection and monitoring strategy.

PCa Commentary | Volume 123 – June 2018

RADIOLIGAND THERAPY (RLT) with 177-LUTETIUM

PSMA is a transmembrane protein of 750 amino acids expressed on the surface of ~90-95% of prostate cancer cells, increasingly expressed as aggressiveness increases. The expression of PSMA is negatively related to androgen receptor abundance so that ADT promotes increased PSMA expression. Its normal function is to ferry nutrients such as folate and glutamate into the cell to support growth and metabolism. Short sections of this convoluted protein molecule can be targeted and linked by small molecules (e.g., “617”) or antibodies (e.g., “J591”). These molecules can be fused to radiation emitting nuclides such as Lutetium-177, Actinium-225, or several others under investigation.

PCa Commentary | Volume 122 – June 2018

New Guidance on the Management of PSA Rise in the Setting of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

At the 2018 Genitourinary Session of the American Association of Clinical Oncology, two presentations reported similar findings which offer management guidance for men whose PSAs are rising despite androgen suppression but have no objective evidence of metastatic spread. For men with metastases, Zytiga and Xtandi are commonly prescribed, but to date there have been no approved treatments for therapy at the nonmetastatic CRPC stage.

PCa Commentary | Volume 121 – April 2018

AR-V7: The Clinical Utility of Knowing Your Status … And When the Information Is Most Useful.

A test for the splice-variant AR-V7, Oncotype Dx AR-V7 Nucleus Detect (Genomic Health, Inc.), has become commercially available. This Commentary will focus on the clinical significance of test results — their predictive and prognostic value.

PCa Commentary | Volume 120 – March 2018

METASTASIS DIRECTED THERAPY:
What Can Be Learned From The First Reported Prospective, Randomized, Multicenter Phase II Clinical Trial?

In December 2017, the JCO published the trial results of Ost and colleagues: “Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence.”1 Up to this time, there have been numerous retrospective and observational studies of varying design which, taken together, strongly suggest that progression-free survival can be prolonged by the focal treatment of three or fewer lesions at the time of PSA recurrence after primary therapy. This regimen is now termed “metastasis-directed therapy” (MDT) and was discussed in detail in an earlier Commentary.

PCa Commentary | Volume 119 – Jan/Feb 2018

KNOW YOUR BRCA STATUS:
The Clinical Importance of Mutations in Genes that Repair Injury to DNA

The message is clear. At diagnosis, 6% of men carry mutations in the BRCA1 or BRCA2 gene. At the stage of metastatic castration-resistant prostate cancer, nearly 12% of men exhibit these germline (inherited) mutations. Finally, as the course of the disease progresses through various therapies, the number of BRCA and BRCA-like mutations further increases and can be found in up to 23% of men.